BNET Industries

Protalex Inc.

Market Cap:$5.7M
  • Public
  • US
Dow Jones Description

In September 1999, Protalex, Inc. ("Protalex" or the "Company") acquired a majority of the issued and outstanding shares of common stock of Enerdyne Corporation from Don Hanosh, pursuant to a Stock Purchase Agreement between Protalex, Enerdyne and Mr. Hanosh. In November 1999, Protalex merged with and into Enerdyne pursuant to a Merger Agreement and Plan of Reorganization, and Enerdyne changed its name to Protalex, Inc. After the merger, Protalex's former stockholders held approximately 92% of the shares of common stock of the Company, and Enerdyne's former stockholders held approximately 8% of the shares of common stock of the Company. The Company is a development stage company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases. The Company's lead product, PRTX-100, has demonstrated effectiveness in pre-clinical studies in regulating the immune system with persisting effects. However, the effectiveness of PRTX-100 shown in pre-clinical studies using animal models may not be predictive of the results that will be realized in clinical trials. The Company currently has no product on the market. The autoimmune diseases initially targeted by the Company are Pemphigus and Rheumatoid Arthritis ("RA").

Contact Information

145 Union Square Drive

New Hope, Pennsylvania 18938

protalex.com

215-862-9720

NAICS Code : 541710

Recent Events

  • Protalex, Inc. Appoints Peter G. Tombros to th...

    6/13/09 - Board Member - Entering - View Story

News & Analysis

protalex inc. - All News and Analysis

advertisement
     PRTX $0.20 +0.04 (25.00% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 27,892
Shares Outstanding 28.60M
Market Cap 5.7M
Year High 0.3
Year Low 0.02
Earnings Per Share -0.25
P/E Ratio -0.80
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement
Click Here